top of page

OUR FOCUS

NK cell derived allogeneic therapies

Natural killer (NK) cells are an ideal foundation for off the shelf (allogeneic) cell therapy development. They are  hard-coded to patrol the body looking for abnormal cells, and naturally perform a number of functions:

01

Natural Detection and Direct Killing of Cancer Cells

NK cells are named 'natural killer' cells based upon their innate ability to recognise and and directly kill cancer without any priming or prior activation. As part of our immune system, they also trigger indirect mechanisms for killing cancer cells. 

02

Indirect Killing of Cancer Cells

Natural killer cells are also able to produce cytokines that recruit and activate the immune system to mount an additional response to kill cancer cells.

02

A universal platform for off the shelf development.

The fact that NK cells  have fail-safe mechanisms that prevent the killing of healthy cells makes them an ideal universal  platform for allogeneic (off the shelf)  development.

CORE NK DIAGRAMS MASTER FINAL_NK CELL.png

NATURAL KILLER (NK) CELL

CHIMERIC 10 TARGET.png

CHM 0201

Core NK platform

The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products.

  • Natural killer cells are found in our bodies naturally and are able to recognize and kill cancer cells – but are not robust and active enough to overcome cancer as it grows

  • CORE-NK platform cells are made by activating and expanding natural killer cells to make them more active and robust

  • CORE-NK platform cells have been studied in a phase 1 clinical trial in blood cancers and solid tumours

CORE NK DIAGRAMS MASTER FINAL_CORE NK PLATFORM.png

CHM 0301

Next gen. core NK platform

The next generation CORE-NK platform will integrate additional activation and expansion features to further optimize the cancer-fighting power of the CORE-NK platform cells.
Development of the next generation CORE-NK platform will be as a combination therapy for blood cancers

CORE NK DIAGRAMS MASTER FINAL_NEXT GEN NK PLATFORM.png

CHM 1301, CHM 2301 AMD CHM 3301

Building upon our core NK platform

Want to know more?

Chimeric Therapeutics is focused upon delivering results for patients, partners and investors.

CHIMERIC 02.png
CHIMERIC 02.png
CORE NK DIAGRAMS MASTER FINAL_BUILDING ON PLATFORM.png

CLTX CAR NK

CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen Receptor.

CORE NK DIAGRAMS MASTER FINAL SHORTER_CLTX CAR NK.png

CDH17 CAR NK

CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen Receptor.

CORE NK DIAGRAMS MASTER FINAL SHORTER_CDH17 CAR NK.png

UNDISCLOSED CAR NK

CHM 3301 (Undisclosed CAR NK) will be developed on the next generation CORE-NK platform leveraging a currently undisclosed Chimeric Antigen Receptor.

CORE NK DIAGRAMS MASTER FINAL SHORTER_U-NDISCLOSED NK.png